Identification of small molecule inhibitors of p27(Kip1) ubiquitination by high-throughput screening. 2013

Li-Ching Ooi, and Nobumoto Watanabe, and Yushi Futamura, and Shaida Fariza Sulaiman, and Ibrahim Darah, and Hiroyuki Osada
Antibiotics Laboratory, RIKEN, Hirosawa, Wako-shi, Saitama, Japan; School of Biological Sciences, Universiti Sains Malaysia, Penang, Malaysia.

Dysregulation of p27(Kip1) due to proteolysis that involves the ubiquitin ligase (SCF) complex with S-phase kinase-associated protein 2 (Skp2) as the substrate-recognition component (SCF(Skp2)) frequently results in tumorigenesis. In this report, we developed a high-throughput screening system to identify small-molecule inhibitors of p27(Kip1) degradation. This system was established by tagging Skp2 with fluorescent monomeric Azami Green (mAG) and CDK subunit 1 (Cks1) (mAGSkp2-Cks1) to bind to p27(Kip1) phosphopeptides. We identified two compounds that inhibited the interaction between mAGSkp2-Cks1 and p27(Kip1): linichlorin A and gentian violet. Further studies have shown that the compounds inhibit the ubiquitination of p27(Kip1) in vitro as well as p27(Kip1) degradation in HeLa cells. Notably, both compounds exhibited preferential antiproliferative activity against HeLa and tsFT210 cells compared with NIH3T3 cells and delayed the G1 phase progression in tsFT210 cells. Our approach indicates a potential strategy for restoring p27(Kip1) levels in human cancers.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D005840 Gentian Violet A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties. Crystal Violet,Methyl Violet,Methylrosaniline Chloride,C.I. 42555,Gentiaanviolet FNA,Hexamethylpararosaniline Chloride,Kristallviolett-Lösung,Vigencial,Chloride, Hexamethylpararosaniline,Chloride, Methylrosaniline,FNA, Gentiaanviolet,Kristallviolett Lösung,Violet, Crystal,Violet, Gentian,Violet, Methyl
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D012717 Sesquiterpenes Fifteen-carbon compounds formed from three isoprenoid units with general formula C15H24. Farnesanes,Farnesene,Farnesenes,Sesquiterpene,Sesquiterpene Derivatives,Sesquiterpenoid,Sesquiterpenoids,Derivatives, Sesquiterpene

Related Publications

Li-Ching Ooi, and Nobumoto Watanabe, and Yushi Futamura, and Shaida Fariza Sulaiman, and Ibrahim Darah, and Hiroyuki Osada
April 2021, ACS pharmacology & translational science,
Li-Ching Ooi, and Nobumoto Watanabe, and Yushi Futamura, and Shaida Fariza Sulaiman, and Ibrahim Darah, and Hiroyuki Osada
May 2023, Bioorganic & medicinal chemistry,
Li-Ching Ooi, and Nobumoto Watanabe, and Yushi Futamura, and Shaida Fariza Sulaiman, and Ibrahim Darah, and Hiroyuki Osada
February 2022, Journal of medicinal chemistry,
Li-Ching Ooi, and Nobumoto Watanabe, and Yushi Futamura, and Shaida Fariza Sulaiman, and Ibrahim Darah, and Hiroyuki Osada
July 2018, Future medicinal chemistry,
Li-Ching Ooi, and Nobumoto Watanabe, and Yushi Futamura, and Shaida Fariza Sulaiman, and Ibrahim Darah, and Hiroyuki Osada
August 2012, Bioscience trends,
Li-Ching Ooi, and Nobumoto Watanabe, and Yushi Futamura, and Shaida Fariza Sulaiman, and Ibrahim Darah, and Hiroyuki Osada
January 2019, Frontiers in microbiology,
Li-Ching Ooi, and Nobumoto Watanabe, and Yushi Futamura, and Shaida Fariza Sulaiman, and Ibrahim Darah, and Hiroyuki Osada
July 2023, Bioorganic & medicinal chemistry,
Li-Ching Ooi, and Nobumoto Watanabe, and Yushi Futamura, and Shaida Fariza Sulaiman, and Ibrahim Darah, and Hiroyuki Osada
March 2023, JHEP reports : innovation in hepatology,
Li-Ching Ooi, and Nobumoto Watanabe, and Yushi Futamura, and Shaida Fariza Sulaiman, and Ibrahim Darah, and Hiroyuki Osada
August 2004, Journal of biomolecular screening,
Li-Ching Ooi, and Nobumoto Watanabe, and Yushi Futamura, and Shaida Fariza Sulaiman, and Ibrahim Darah, and Hiroyuki Osada
October 2016, Antiviral research,
Copied contents to your clipboard!